Tech Company Financing Transactions
Apriori Bio Funding Round
Apriori Bio secured a $1.1 million investment round on 7/8/2024. Investors included CEPI (Coalition for Epidemic Preparedness Innovations).
Transaction Overview
Company Name
Announced On
7/8/2024
Transaction Type
Venture Equity
Amount
$1,100,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to biology-informed artificial intelligence platform Octavia�.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
55 Cambridge Parkway 800E
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Dangerous viruses pose a global, persistent, and unavoidable threat to humanity. Our pioneering approach centers on a unique technology platform which allows us to survey the entire landscape of existing and potential variants to design new vaccines against the most threatening viruses. Apriori was founded by Flagship Pioneering to provide humanity with variant-resilient protection against rapidly-evolving viruses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Noubar Afeyan
Chief Executive Officer
Lovisa Afzelius
Chief Information Officer
Daniel Acker
Chief Marketing Officer
Hutan Ashrafian
Chief Operating Officer
Alex Goldsmith
Chief Scientific Officer
Hozefa Bandukwala
President
Craig Williams
VP - R & D
Patrick Jones
VP - Regulatory Affairs
Tom Kibasi
Browse more venture capital transactions:
Prev: 7/8/2024: Thrive AI Health venture capital transaction
Next: 7/8/2024: Planqc venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs